Literature DB >> 7629398

Neuropeptide Y: a possible role in hypertension?

M C Michel1, W Rascher.   

Abstract

PURPOSE: To evaluate whether neuropeptide Y (NPY) is likely to be relevant as a regulator of cardiovascular function in general and of blood pressure control in arterial hypertension in particular, based on a literature survey. RESULTS OF DATA ANALYSIS: NPY is a putative cotransmitter of many central and peripheral sympathetic neurons. It and its receptors are present in brain areas and peripheral tissues involved in cardiovascular regulation, and administration of exogenous NPY to these sites can elicit functional cardiovascular responses by acting on specific pre- and postsynaptic receptors. Moreover, NPY may act as a growth factor for the development of vascular and cardiac hypertrophy. The release of NPY and postsynaptic vasoconstriction responses to NPY may be enhanced in hypertension, whereas presynaptic inhibitory responses may be attenuated. Some of these alterations may precede the development of blood pressure elevations in the spontaneously hypertensive rat model of genetic hypertension.
CONCLUSIONS: NPY might be an important physiological and pathophysiological modulator of cardiovascular function, but further studies using specific high-affinity antagonists are required.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7629398

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  13 in total

Review 1.  Neuropeptide Y T1128C polymorphism: an independent predictor of hypertensive and cardiovascular diseases?

Authors:  Jia L Zhuo
Journal:  J Hypertens       Date:  2004-07       Impact factor: 4.844

2.  Effects of noradrenaline and neuropeptide Y on rat mesenteric microvessel contraction.

Authors:  H Chen; C Fetscher; R F Schäfers; G Wambach; T Philipp; M C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-02       Impact factor: 3.000

Review 3.  Early life obesity and chronic kidney disease in later life.

Authors:  Hyung Eun Yim; Kee Hwan Yoo
Journal:  Pediatr Nephrol       Date:  2014-08-22       Impact factor: 3.714

4.  Metabolism and functions of neuropeptide Y.

Authors:  M dos S Medeiros; A J Turner
Journal:  Neurochem Res       Date:  1996-09       Impact factor: 3.996

Review 5.  Neuronal and non-neuronal modulation of sympathetic neurovascular transmission.

Authors:  H Macarthur; G H Wilken; T C Westfall; L L Kolo
Journal:  Acta Physiol (Oxf)       Date:  2011-03-01       Impact factor: 6.311

6.  Mechanism of dopamine mediated inhibition of neuropeptide Y release from pheochromocytoma cells (PC12 cells).

Authors:  Guihua Cao; Alice Gardner; Thomas C Westfall
Journal:  Biochem Pharmacol       Date:  2007-01-07       Impact factor: 5.858

7.  Neuropeptide Y promoter polymorphism modifies effects of a weight-loss diet on 2-year changes of blood pressure: the preventing overweight using novel dietary strategies trial.

Authors:  Xiaomin Zhang; Qibin Qi; Jun Liang; Frank B Hu; Frank M Sacks; Lu Qi
Journal:  Hypertension       Date:  2012-09-10       Impact factor: 10.190

Review 8.  Neuropeptide Y and neurovascular control in skeletal muscle and skin.

Authors:  Gary J Hodges; Dwayne N Jackson; Louis Mattar; John M Johnson; J Kevin Shoemaker
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-07-01       Impact factor: 3.619

9.  Effect of amlodipine on the growth of vascular smooth muscle cells of spontaneously hypertensive rats.

Authors:  J Tang; Z Liu; D Ren; C Wu
Journal:  J Tongji Med Univ       Date:  1997

10.  Contribution of alpha2-adrenoceptors and Y1 neuropeptide Y receptors to the blunting of sympathetic vasoconstriction induced by systemic hypoxia in the rat.

Authors:  Andrew M Coney; Janice M Marshall
Journal:  J Physiol       Date:  2007-05-17       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.